DCTH / Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates

Delcath Systems (NASDAQ: DCTH ) stock is rocketing higher on Tuesday after getting an update from the FDA. This has the FDA approving HEPZATO KIT. more_horizontal

Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prep more_horizontal

Delcath Systems Inc. (NASDAQ:DCTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Gerard Michel - Chief Executive Offi more_horizontal

NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary an more_horizontal

Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Comp more_horizontal

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the num more_horizontal

Delcath Systems (DCTH) CEO, Gerard Michel on Q4 2021 Results - Earnings Call Transcript more_horizontal

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the more_horizontal